CD4 and relapsing-remitting multiple sclerosis: We, and others, have used genome-wide DNA methylation technologies to assess differentially methylated regions (DMRs) of CD4+ and CD8+ T cells in relapsing-remitting multiple sclerosis (RRMS) patients compared to healthy controls [7–10].